 Home > Medical News > Latest Medical News > Tianyao: Methylprednisolone sodium succinate for injection passed the consistency evaluation

Tianyao: Methylprednisolone sodium succinate for injection passed the consistency evaluation

 Last Update: 2021-06-04
 Source: Internet
 Author: User

Tags

quartz level 1

anthrax drug

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On May 31, Tianyao said that its subsidiary Tianjin Jinyao Pharmaceutical Co.

Methylprednisolone sodium succinate for injection is a glucocorticoid drug, mainly used for anti-inflammatory treatment, immunosuppressive treatment, blood disease and tumor treatment, shock treatment, etc.

The original manufacturer of methylprednisolone sodium succinate for injection was Pfizer, USA, under the trade name SOLU-MEDROL.

According to relevant national policies and regulations, appropriate support will be provided in terms of medical insurance payment for drug varieties that have passed the consistency evaluation, and medical institutions should give priority to procurement and give priority to clinical selection.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.